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Background: Visceral fat accumulation is caused by over-nutrition and physical inactivity. Excess accumulation of
visceral fat associates with atherosclerosis. Polyunsaturated fatty acids have an important role in human nutrition,
but imbalance of dietary long-chain polyunsaturated fatty acids, especially low eicosapentaenoic acid (EPA) /
arachidonic acid (AA) ratio, is associated with increased risk of cardiovascular disease. The present study
investigated the correlation between EPA, docosahexaenoic acid (DHA), AA parameters and clinical features in male
subjects.
Findings: The study subjects were 134 Japanese with diabetes, hypertension and/or dyslipidemia who underwent
measurement of visceral fat area (eVFA) by the bioelectrical impedance method and serum levels of EPA, DHA and
AA. EPA/AA ratio correlated positively with age, and negatively with waist circumference and eVFA. Stepwise
regression analysis demonstrated that age and eVFA correlated significantly and independently with serum EPA/AA
ratio. Serum EPA/AA ratio, but not serum DHA/AA and (EPA+DHA)/AA ratios, was significantly lower in subjects
with eVFA ≥100 cm2, compared to those with eVFA <100 cm2 (p=0.049). Subjects with eVFA ≥100 cm2 were
significantly more likely to have the metabolic syndrome and history of cardiovascular diseases, compared to those
with eVFA <100 cm2 (p<0.001, p=0.028, respectively).
Conclusions: Imbalance of dietary long-chain polyunsaturated fatty acids (low serum EPA/AA ratio) correlated with
visceral fat accumulation in male subjects.
Clinical trial registration number: UMIN000002271
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ObesityBackground
Obesity, especially excess accumulation of visceral fat, is
upstream of obesity-related disorders including atheroscle-
rotic cardiovascular disease [1]. Visceral fat accumulation
represents positive energy balance, conditioned by genetic
and environmental factors, such as high-fat and/or high
sucrose diet, physical inactivity, sleep-disorders, and mental
stress [1]. Polyunsaturated fatty acids have an important
role in human diet, both in the prevention and treatment of
pathologies [2,3]. Previous studies reported that an imba-
lance of dietary long-chain polyunsaturated fatty acids, es-
pecially low omega-3/omega-6 polyunsaturated fatty acids* Correspondence: kkishida@imed2.med.osaka-u.ac.jp
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reproduction in any medium, provided the orratio, is associated with increased risk of cardiovascular
disease [4-6]. To our knowledge, the relationship between
visceral fat volume and omega-3/omega-6 polyunsaturated
fatty acid ratio has not yet been characterized. The present
study investigated the correlation between omega-3 poly-
unsaturated fatty acid (eicosapentaenoic acid [EPA],
docosahexaenoic acid [DHA]), omega-6 polyunsaturated
fatty acid (arachidonic acid [AA], and clinical features in
male subjects.Methods and procedures
Study population
The study subjects were 134 consecutive Japanese subjects
with diabetes, hypertension and/or dyslipidemia, who
visited the outpatient clinic of “Diabetes & Metabolic
Station” at Osaka University Hospital, between Septembertd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.




Body mass index (BMI), kg/m2 25.6±3.9
(18.1-38.5)
Waist circumference (WC), cm 90.6±10.7
(68–130)
Estimated visceral fat area (eVFA), cm2 142±60
(36–371)




(calcium channel antagonist / angiotensin converting
enzyme inhibitor or angiotensin receptor blocker /
eplerenone / aliskiren fumarate / beta blockade /
diuretics / alpha blockade )
(n=49/60/1/1/13/
15/2)
Systolic blood pressure (SBP), mmHg 132±16 (94–180)
Diastolic blood pressure (DBP), mmHg 76±11 (52–111)
Diabetes (%) 78.4
(sulfonyl ureas / glinides / biguanides / pioglitazone /
alpha glucosidase
inhibitors / dipeptidyl peptidase-IV inhibitors /
glucagon-like peptide-1 agonists / Insulin)
(n=42/3/25/24/
21/11/1/20)
Fasting blood glucose (FBG), mg/dL 128±35 (56–261)
Hemoglobin A1c (HbA1c), (NGSP),% 6.9±1.1 (4.9-10.7)
HOMA-IR, units 3.1±2.4 (0.47-
14.1)
Estimated glomerular filtration rate (eGFR), mL/min 69.5±17.7
(24.4-110.6)





(statins / fibrates / ezetimibe / cholestimide /
probucol)
(n=59/3/5/1/2)
Total cholesterol (T-cho), mg/dL 192±37
(112–335)
Low-density lipoprotein-cholesterol (LDL-C), mg/dL 112±33 (55–259)
Triglyceride (TG), mg/dL 142±91 (32–681)
High-density lipoprotein-cholesterol (HDL-C), mg/dL 53±16 (23–157)
Metabolic syndrome (%) 55.2
Eicosapentaenoic acid (EPA), μg/mL 63.8±35.7
(11.1-212.4)
Docosahexaenoic acid (DHA) , μg/mL 140.0±67.3
(41–610.3)








History of coronary artery diseases (CAD) (%) 39.6
Data are mean ± SEM (range), or number of subjects. HOMA-IR, homeostasis
model assessment of insulin resistance.
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Osaka University approved this study. All participants
were Japanese and each gave a written informed consent.
This study (ADMIT study) is registered under number
UMIN000002271.
Definition of coronary artery diseases
Documented coronary artery diseases (CAD) encompassed
one or more of the following: history of stable with docu-
mented CAD evaluated with stress electrocardiography,
such as ergometry or double master’s two-step test,
multi-detector row computed tomography or coronary
angiography; history of previous acute coronary syndrome
including unstable angina and myocardial infarction evalu-
ated with coronary angiography and underwent percuta-
neous coronary intervention or coronary artery bypass
graft surgery.
Anthropometric data and laboratory tests
Anthropometric variables [height, weight and waist cir-
cumference (WC)] were measured in the standing po-
sition. WC at the umbilical level was measured with a
non-stretchable tape in late expiration while standing
(in cm). Body mass index (BMI) was calculated using the
formula [weight(kg)/height(m)2]. Visceral fat area was
estimated by the bioelectrical impedance analysis me-
thod (eVFA), as reported previously by our group [7].
Briefly, the voltage recorded at the flank to the flow of
current between the umbilicus and the back correlates
significantly with visceral fat area and is not influenced
by the amount of subcutaneous fat. We demonstrated
previously that eVFA correlates significantly with that
determined by computed tomography [7]; the coefficient
of variation of the bioelectrical impedance analysis
method with the computed tomography value was 0.89%
in the standing posture and late expiration.
Blood pressure was measured with a standard mercury
sphygmomanometer on the right arm in the supine
position after at least 10-minute rest. After overnight
fasting state, venous blood samples were collected for
measurements of blood glucose, hemoglobin A1c (HbA1c)
[National Glycohemoglobin Standardization Program
(NGSP)], triglyceride, and high-density lipoprotein-
cholesterol (HDL-C), uric acid, and creatinine. Low-
density lipoprotein-cholesterol (LDL-C) was calculated
with the Friedewald equation. Urine albumin-creatinine
ratio (UACR) was calculated from a single spot urine
specimen collected between morning and afternoon.
Urine albumin concentration was determined by the
immunoturbidimetric method (N-assay TIA MicroAlb,
Nittobo Medical, Japan). Estimated GFR (eGFR) was calcu-
lated using the simplified Modification of Diet in Renal
Disease equation modified by the appropriate coefficient
for Japanese populations by gender, as described previously
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(HOMA-IR) was calculated using the following formula:
HOMA − IR (milliunits per liter×milligrams per deciliter) =
[(fasting IRI(microunit/mL) × fasting glucose [mg/mL])/405].
Measurement of serum EPA, DHA and AA levels was
outsourced to SRL (Tokyo, Japan). In brief, plasma lipids
were extracted by Folch’s procedure, and then fatty acids
(tricosanoicacid, C23:0, as the internal standard) were
methylated with boron trifluoride and methanol. The
methylated fatty acids were then analyzed using a capillary
gas chromatograph (GC-2010; Shimadzu, Kyoto, Japan).
Subjects were divided according to smoking habit into
current or ex-smokers and non-smokers. Diabetes mellitus
was defined according to World Health Organization
criteria or regular treatment with anti-diabetic agents.
Dyslipidemia was defined as total cholesterol concentration
of ≥220mg/dL, triglyceride concentration ≥150mg/dL,
HDL-C concentration <40mg/dL, or regular treatment
with anti-lipidemic agents. Hypertension was defined as sys-
tolic blood pressure ≥140mmHg, diastolic blood pressure
≥90mmHg, or regular treatment with anti-hypertensive
agents. Patients with a previous diagnosis of dyslipidemia,
hypertension, or diabetes mellitus and receiving drugs for
any of these conditions were also included in this study.
The metabolic syndrome was diagnosed according to the
Japanese criteria for the metabolic syndrome [9].
Statistical analysis
All values were expressed as mean±SD. Data of eVFA, and
triglyceride levels showed skewed distribution, and were
therefore log-transformed before analysis. Relationships be-
tween two continuous variables were analyzed using scatter
plots and Pearson’s correlation coefficients. Data of the two
groups were compared by the Student’s t-test or the(A) EPA (B) DHA
(D) EPA/AA (E) DHA/A
median=13median=55.7
median=0.34 median=0.
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Figure 1 Distribution of eicosapentaenoic acid (EPA), docosahexaeno
(EPA+DHA)/AA ratio.Mann–Whitney test. The frequencies were compared be-
tween two groups by the χ2 test. The correlations between
EPA,DHA, AA, EPA/AA, DHA/AA, (EPA+DHA)/AA and
other parameters were first analyzed by simple regression
analysis and then by multivariate stepwise analysis. In all
cases, p values <0.05 were considered statistically signifi-
cant. All analyses were performed with the JMP Statistical
Discovery Software 8.0 (SAS Institute, Cary, NC).
Results
Subjects’ characteristics
Table 1 summarizes the characteristics of all male sub-
jects enrolled in this study. Visceral fat accumulation
(eVFA ≥100 cm2) based on Japanese criteria of visceral fat
accumulation [10] was identified in 76.9% (n=103/134).
Figure 1 showed the distribution of EPA, DHA, AA,
EPA/AA, DHA/AA and (EPA+DHA)AA ratios.
Correlation between serum levels of EPA, DHA, AA, EPA/
AA DHA/AA, (EPA+DHA)AA ratios and clinical features
Table 2 and 3 summarize the results of correlation analyses
of serum levels of EPA, DHA, AA, EPA/AA, DHA/AA,
(EPA+DHA)/AA ratios with various clinical parameters.
EPA correlated significantly and positively with LDL-C,
HDL-C, DHA, and AA. Stepwise regression analysis that
included LDL-C, HDL-C, DHA, and AA identified HDL-C,
DHA, and AA correlated significantly and independently
with EPA. DHA correlated significantly and positively with
LDL-C, log-TG, EPA, and AA. Stepwise regression analysis
that included LDL-C, log-TG, EPA, and AA identified log-
TG, EPA, and AA correlated significantly and indepen-
dently with DHA. AA correlated significantly and negatively
with age, and positively with BMI, WC, eVFA, HOMA-IR,
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ic acid (DHA), arachidonic acid (AA), EPA/AA ratio, DHA/AA ratio,
Table 3 Correlations between serum EPA/AA, DHA/AA, (EPA+DHA)/AA ratios and various parameters
Serum EPA/AA ratio Serum DHA/AA ratio Serum (EPA+DHA)/AA ratio
Univariate Multivariate Univariate Univariate
r p value p value r p value r p value
Age 0.242 0.005 0.003 0.296 0.001 0.295 <0.001
BMI −0.162 0.061 −0.127 0.144 −0.154 0.076
WC −0.176 0.042 - −0.117 0.179 −0.153 0.077
Log-eVFA −0.212 0.015 0.026 −0.097 0.269 −0.157 0.071
Brinkman index −0.081 0.696 −0.081 0.359 −0.066 0.453
SBP 0.079 0.679 0.135 0.120 0.100 0.251
DBP −0.076 0.631 0.056 0.521 0.015 0.867
FBG −0.009 0.919 −0.016 0.856 −0.016 0.851
HbA1c −0.010 0.915 −0.015 0.863 −0.013 0.879
HOMA-IR −0.064 0.543 −0.032 0.763 −0.047 0.654
eGFR 0.045 0.614 −0.079 0.373 −0.029 0.740
UACR 0.043 0.674 0.035 0.729 0.041 0.684
LDL-C 0.063 0.481 0.058 0.514 0.065 0.463
HDL-C 0.098 0.264 0.45 0.611 0.072 0.409
Log-TG −0.154 0.076 0.074 0.396 −0.026 0.767
Data are mean ± SEM (range), or number of subjects. Abbreviations as in Table 1. Parameters with p<0.05 in univariate analysis were subsequently entered into
stepwise regression analysis as significant and independent variables. EPA/AA (adopted parameters; age, eVFA).
Table 2 Correlations between serum EPA, DHA, AA, and various parameters
Serum EPA Serum DHA Serum AA
Univariate Multivariate Univariate Multivariate Univariate Multivariate
r p value p value r p value p value r p value p value
Age 0.066 0.449 −0.019 0.829 −0.381 <0.001 0.002
BMI −0.049 0.577 0.064 0.465 0.216 0.012 0.952
WC −0.083 0.342 0.042 0.632 0.172 0.048 -
Log-eVFA −0.108 0.218 0.058 0.506 0.203 0.020 0.242
Brinkman index −0.111 0.207 −0.139 0.114 −0.091 0.300
SBP 0.049 0.571 0.101 0.244 −0.029 0.739
DBP −0.016 0.857 0.058 0.503 0.022 0.801
FBG −0.029 0.745 −0.013 0.886 0.024 0.786
HbA1c −0.059 0.510 −0.072 0.416 −0.059 0.503
HOMA-IR 0.063 0.547 0.136 0.193 0.228 0.028 0.909
eGFR 0.045 0.608 −0.030 0.732 0.160 0.038 0.353
UACR 0.155 0.126 0.150 0.138 0.076 0.455
LDL-C 0.233 0.008 0.142 0.256 0.004 0.424 0.236 0.007 0.835
HDL-C 0.181 0.037 0.030 0.113 0.196 0.122 0.161
Log-TG 0.087 0.320 0.371 <0.001 <0.001 0.403 <0.001 0.390
EPA 0.757 <0.001 <0.001 0.251 0.004 0.259
DHA 0.757 <0.001 <0.001 0.517 <0.001 <0.001
AA 0.251 0.004 0.001 0.517 <0.001 <0.001
Data are mean ± SEM (range), or number of subjects. Abbreviations as in Table 1. Parameters with p<0.05 in univariate analysis were subsequently entered into
stepwise regression analysis as significant and independent variables. EPA (adopted parameters; LDL-C, HDL-C, DHA, AA), DHA (adopted parameters; LDL-C, Log-
TG, EPA, AA), AA (adopted parameters; age, BMI, Log-eVFA, HOMA-IR, eGFR, LDL-C, log-TG, EPA, DHA).
Inoue et al. Nutrition & Metabolism 2013, 10:25 Page 4 of 8
http://www.nutritionandmetabolism.com/content/10/1/25
Inoue et al. Nutrition & Metabolism 2013, 10:25 Page 5 of 8
http://www.nutritionandmetabolism.com/content/10/1/25analysis that included age, BMI, eVFA, HOMA-IR, eGFR,
LDL-C, log-TG, EPA, and DHA, demonstrated that age and
DHA correlated significantly and independently with AA.
The EPA/AA ratio correlated significantly and positively
with age, and negatively WC and eVFA. Stepwise regres-
sion analysis demonstrated that age and eVFA correlated
significantly and independently with EPA/AA ratio. The
DHA/AA ratios and (EPA+DHA)/AA ratios correlated
significantly and positively with age only.
Serum AA levels correlated positively with eVFA and
serum EPA/AA and (EPA+DHA)/AA levels correlated
negatively with eVFA, however, there was no significant
correlation between EPA, DHA, DHA/AA ratio, and eVFA
(Figure 2).Comparisons of clinical features in subjects with eVFA
<100 cm2 and ≥100 cm2
Table 4 shows the characteristics of subjects with eVFA
<100 cm2 and ≥100 cm2 based on Japanese criteria of vis-
ceral fat accumulation [9]. The proportion of patients with











































Figure 2 Correlations between EPA, DHA, AA, EPA/AA ratio, DHA/AA
Pearson’s correlation coefficient was used to examine the relationship betw
and eVFA. Abbreviations as in Figure 1.triglyceride were significantly higher in the eVFA ≥100 cm2
group, compared to the eVFA <100 cm2 group. Serum
HDL-C levels were significantly lower in subjects with
eVFA ≥100 cm2, than those with eVFA <100 cm2. Diffe-
rences in serum EPA, DHA, and AA levels were not signifi-
cant between the two groups (Figure 3A-C). Serum EPA/AA
ratio, but not serum DHA/AA and (EPA+DHA)/AA ra-
tios, was significantly lower in the eVFA ≥100 cm2 group,
compared to the eVFA <100 cm2 group (Figure 3D-F). A
larger proportion of subjects with eVFA ≥100 cm2 were
diagnosed with the metabolic syndrome and cardiovas-
cular diseases, compared to those with eVFA <100 cm2
(Figure 4A,B).
Discussion
The following were the major findings of the present
study: 1) stepwise analysis demonstrated that age and
eVFA correlated significantly and independently with
serum EPA/AA ratio, and 2) Subjects with eVFA ≥100 cm2
had lower serum EPA/AA ratio and were more likely to
have metabolic syndrome and history of CAD, compared











































ratio, (EPA+DHA)/AA ratio, and estimated visceral fat area (eVFA).
een EPA, DHA, AA, EPA/AA ratio, DHA/AA ratio, (EPA+DHA)+AA ratios,
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minary studies analyzed the difference of serum EPA/AA
ratio in female subjects with eVFA <100 cm2 and ≥100
cm2 (n=100, data not shown). There was no significant dif-
ference of serum EPA/AA ratio in between female subjects
with eVFA <100 cm2 and ≥100 cm2 (n=61/39, 0.37±0.27
versus 0.38±0.25, p=0.9236), and the two groups had lower
serum EPA/AA levels. These data suggested that Japanese
females may have an aversion to fish intake. Further stu-
dies including larger number of female subjects with eVFA
≥100 cm2 are needed to clarify the correlation between
serum EPA/AA and eVFA.
In Japan, the percentage of high-fat food intake from
animal sources per total daily calories has been increa-
sing every year, based on the annual reports of the Min-
istry of Health, Labour and Welfare (http://www0.nih.go.
jp/eiken/chosa/kokumin_eiyou/). The optimal dietary fat
profile includes low intake of both saturated and omega-
6 fatty acids and a moderate intake of omega-3 fatty
acids [11]. Omega-3 and omega-6 fatty acids are essential
because they are not synthesized by the body and must be
obtained through diet or supplementation [12]. Omega-6
fatty acids, which are present in most seeds, vegetable oils,
and meat, are prothrombotic and proinflammatory [12].
In contrast, omega-3 fatty acids, eicosapentaenoic acidTable 4 Comparison of various parameters between subjects
eVFA <100 cm2 group
n (Male) 31
Age, years 62±16 (25–86)
BMI, kg/m2 21.7±1.9 (18.1-25.8)
WC, cm 78.0±4.6 (68–90)
History of smoking (%) 67.7
Brinkman index 591±699 (0–3000)
Hypertension (%) 41.9
SBP, mmHg 127±17 (94–168)
DBP, mmHg 71±9 (52–91)
Diabetes (%) 71.0
FBG, mg/dL 119±35 (80–216)
HbA1c, (NGSP),% 6.8±1.1 (4.9-8.9)
HOMA-IR, units 2.0±1.9 (0.47-8.0)
eGFR, mL/min 72.3±16.8 (43.0-103.4)
UACR, mg/g creatinine 244.6±869.9 (0.5-3958)
Dyslipidemia (%) 54.8
T-cho, mg/dL 198±38 (137.8-271)
LDL-C, mg/dL 117±35 (68–182)
TG, mg/dL 87±35 (32–182)
HDL-C, mg/dL 63±24 (31–157)
Data are mean ± SEM (range), or number of subjects. Abbreviations as in Table 1. Pand docosahexaenoic acid, which are present in most fish,
such as salmon and tuna, and fish oil, are anti-thrombotic
and anti-inflammatory [12]. The present study demon-
strated a negative correlation between EPA/AA ratio and
visceral fat area (Figure 2 and Table 3). Experimental and
clinical studies suggest that insulin resistance could
explain this negative relationship. Previous studies in dia-
betic rats demonstrated that long-term intake of EPA
prevented insulin resistance, at least in part by improving
hypertriacylglycerolemia [13]. Furthermore, low EPA/AA
ratio, which is associated with insulin resistance, was also
reported in young Japanese adults [14]. Another study
demonstrated that the omega-3/omega-6 ratio correlated
with HOMA-IR levels in subjects with the metabolic syn-
drome [15].
Our results demonstrated that subjects with eVFA ≥100
cm2 had lower serum EPA/AA ratio, but not serum
DHA/AA, and were more likely to have history of CAD,
compared to those with eVFA <100 cm2. A low ratio of n-3
to n-6 polyunsaturated fatty acids is associated with cardio-
vascular events [4,6,16-18]. However, either study had ana-
lyzed the patients with CAD or ischemic stroke, i.e.
secondary preventive groups. The present study in lifestyle-
related subjects suggests that low EPA/AA ratio may be
important in primary prevention of cardiovascular events.with eVFA <100 cm2 and eVFA ≥100 cm2
















































































































Figure 3 Circulating levels of EPA, DHA, AA, EPA/AA ratio,
DHA/AA ratio, and (EPA+DHA)/AA ratio in subjects with eVFA
<100 cm2 and ≥100cm2. Data are mean±SEM. Statistical
comparisons by the Mann–Whitney U-test or Student’s t-test.
Abbreviations as in Figure 1.
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meat intake, i.e., low EPA/AA ratio, may explain at least in
part the worldwide trend of increased prevalence of the
metabolic syndrome and atherosclerotic cardiovascular
diseases. Intervention with fish oil supplements high in




































Figure 4 Prevalence of metabolic syndrome and cardiovascular
diseases (CAD) in subjects with eVFA <100 cm2 and ≥100cm2.
Data are mean±SEM. Statistical comparisons by the Mann–Whitney
U-test or Student’s t-test. Abbreviations as in Figure 1.patients with substantial reduction in the risk of sudden
cardiac death [19,20]. Further intervention trials are
needed to address the effect of balanced EPA/AA diet on
the incidence of the metabolic syndrome.
In conclusion, the present study showed that low
EPA/AA ratio correlated with visceral fat accumulation
in male subjects, and subjects with eVFA ≥100 cm2 had
lower serum EPA/AA ratio and were more likely to have
the metabolic syndrome and history of cardiovascular
disease, compared to those with eVFA <100 cm2. The
balance of EPA/AA by lifestyle modification and medica-
tion (such as EPA-based medications) could be useful in
reducing the prevalence of the metabolic syndrome and
atherosclerosis.
Study limitations
The present study has certain limitations. First, this is a
cross-sectional study, making it difficult to establish a
cause-effect relationship. Second, the results may not
be applicable to females or non-Japanese populations.
Third, there is bias in single center trials. Fourth, the
number of patients may be relatively small. Finally, our
study measured abdominal visceral fat area by the bio-
electrical impedance method. Measurements of both
visceral and subcutaneous fat areas by computed to-
mography are more accurate.
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